Published in Am J Cancer Res on July 15, 2015
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Repairing DNA-methylation damage. Nat Rev Mol Cell Biol (2004) 2.85
DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol (2013) 1.57
Single-trial coupling of the gamma-band response and the corresponding BOLD signal. Neuroimage (2009) 0.97
Antitumor imidazotetrazines. 41. Conjugation of the antitumor agents mitozolomide and temozolomide to peptides and lexitropsins bearing DNA major and minor groove-binding structural motifs. J Med Chem (2002) 0.94
DNA breaks and chromosomal aberrations arise when replication meets base excision repair. J Cell Biol (2014) 0.92
Monitoring of buccal epithelial cells by alkaline comet assay (single cell gel electrophoresis technique) in cytogenetic evaluation of chlorhexidine. Clin Oral Investig (2002) 0.91
The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy. Radiat Oncol (2012) 0.89
High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. BMC Cancer (2014) 0.88
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer. Onkologie (2007) 0.86
Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin. Prostate (2011) 0.85
The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res (2007) 0.83
Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide. Cancer Gene Ther (2000) 0.83
ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol (2013) 0.83
"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. Prostate (2012) 0.82
Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class. Drug Metab Lett (2009) 0.82
Subcellular distribution of a fluorescence-labeled combi-molecule designed to block epidermal growth factor receptor tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther (2010) 0.81
Reversal effect of BM-cyclin 1 on multidrug resistance by down-regulating MRP2 in BALB/C nude mice bearing C-A120 cells. J Huazhong Univ Sci Technolog Med Sci (2013) 0.81
Environmental and psycho-social factors related to prostate cancer risk in the Chinese population: a case-control study. Biomed Environ Sci (2014) 0.81
Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chem Biol Drug Des (2008) 0.79
[Incidence and clinicopathological characteristics of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens]. Beijing Da Xue Xue Bao (2014) 0.78
Acidic extracellular microenvironment promotes the invasion and cathepsin B secretion of PC-3 cells. Int J Clin Exp Med (2015) 0.75